Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 17/20 | 1.00 |
| ▸ | RXRA | P19793 | 17/20 | 1.00 |
| ▸ | RARG | P13631 | 16/20 | 1.00 |
| ▸ | RARA | P10276 | 11/20 | 1.00 |
| ▸ | RXRB | P28702 | 7/20 | 1.00 |
| ▸ | RXRG | P48443 | 7/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.72 |
| ▸ | RECQL | P46063 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | GMNN | O75496 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301839 | 1.00 | RARB (1.00) | RARBRXRARARGRARARXRB | |
| SCHEMBL3301842 | 1.00 | RARB (1.00) | RARBRXRARARGRARARXRB | |
| SCHEMBL10845294 | 0.92 | RARB (0.85) | RARBRXRARARGRARARXRB | |
| SCHEMBL10845299 | 0.92 | RARB (0.85) | RARBRXRARARGRARARXRB | |
| 4-Aminophenol SCHEMBL10844811 | 0.90 | RARB (0.81) | RARBRXRARARGRARARXRB | |
| 4-Aminophenol SCHEMBL10844822 | 0.90 | RARB (0.81) | RARBRXRARARGRARARXRB | |
| SCHEMBL7223850 | 0.87 | RARB (1.00) | RARBRXRARARGRARARXRB | |
| SCHEMBL7225160 | 0.87 | RARB (1.00) | RARBRXRARARGRARARXRB | |
| SCHEMBL7223854 | 0.87 | RARB (1.00) | RARBRXRARARGRARARXRB | |
| SCHEMBL7225152 | 0.87 | RARB (1.00) | RARBRXRARARGRARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827408-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | Nu-Tein Co., Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| US-7223397-B1 | Potentiation of anti-CD38-Immunotoxin cytotoxicity | RESEARCH DEVELOPMENT FOUNDATION (US) | 2007-05-29 | — | — | US | claimed |
| WO-2006060475-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. | 2006-06-08 | — | — | US | claimed |
| EP-0465343-B1 | Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association | CIRD GALDERMA (FR) | 1994-06-15 | — | — | EP | claimed |
| US-4877805-A | REVERSING COLLAGEN FIBER LOSS BY APPLYING TO FACE | KLIGMAN ALBERT M (US) | 1989-10-31 | — | — | US | claimed |
| WO-2017180440-A1 | DELIVERY SYSTEM BASED ON A NATURAL MICROPARTICLE FOR USE IN PERSONAL CARE AND OTHER TOPICAL APPLICATIONS | AMCOL INTERNATIONAL CORPORATION (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20080255244-A1 | Administering a Calmodulin-dependent protein kinase (M kinase II) gamma inhibitor; acute myelogenous leukemia, chronic myelogenous leukemia, gastrointestinal stromal tumor, small cell lung cancer, non-small cell lung cancer, ovarian cancer | FRED HUTCHINSON CANCER RESEARCH CENTER | 2008-10-16 | — | — | US | disclosed |
| US-7223397-B1 | Potentiation of anti-CD38-Immunotoxin cytotoxicity | RESEARCH DEVELOPMENT FOUNDATION (US) | 2007-05-29 | — | — | US | disclosed |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. | 2006-06-08 | — | — | US | disclosed |
| EP-0781551-B1 | Retinoid formulations in porous microspheres for reduced irritation and enhanced stability | ENHANCED DERM TECHNOLOGIES INC (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6221618-B1 | DETECTION OF MODULATORS WHICH SUPPRESSES CARDIOVASCULAR DISORDERS; INCUBATE HEART MUSCLE CELLS WITH INDUCER OF CARDIOVASCULAR DISORDERS, MEASURE DEVELOPMENT OF HYPERTROPHY | CHIEN KENNETH R (US) | 2001-04-24 | — | — | US | disclosed |
| US-6060311-A | IDENTIFYING A COMPOUND THAT INHIBITS RETINOIC ACID SUPPRESSION OF VENTRICULAR MUSCLE CELL HYPERTROPHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |
| US-5968981-A | ENDOTHELINS AND ALPHA-ADRENERGIC AGONIST USING RETINOIDS FOR CARDIOVASCULAR DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0781551-A1 | Retinoid formulations in porous microspheres for reduced irritation and enhanced stability | Advanced Polymer Systems, Inc. (US) | 1997-07-02 | — | — | EP | disclosed |
| WO-1997004766-A1 | RETINOID SUPPRESSION OF VENTRICULAR MUSCLE CELL HYPERTROPHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-02-13 | — | — | WO | disclosed |
| US-5587367-A | SYNERGISTIC EFFECT IN TREATING SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-12-24 | — | — | US | disclosed |
| US-5534261-A | Retinoid-based compositions and method for preventing adhesion formation using the same | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1996-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | COL1A1, COL2A1, KRT18 | RARB 369/4885RXRA 21/4885RARG 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.